Baqsimi ® (glucagon) nasal powder


This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can both Baqsimi™ (glucagon) nasal powder and glucagon for injection be used in a single hypoglycemic event?

There have been no studies conducted on the use of both Baqsimi and glucagon for injection to treat a single, severe hypoglycemic event


Use of Both Baqsimi and Glucagon for Injection

The recommended dose of Baqsimi is 3 mg administered as one actuation of the intranasal device into one nostril.1

Call for emergency assistance immediately after administering the dose.1

If there has been no response after 15 minutes, an additional 3 mg dose of Baqsimi from a new device may be administered while waiting for emergency assistance.1

There have been no studies conducted on the administration of Baqsimi and glucagon for injection, either Baqsimi followed by glucagon for injection or glucagon for injection followed by Baqsimi, to treat a single, severe hypoglycemic event. Thus, Eli Lilly and Company has no information on this usage of Baqsimi and glucagon for injection.2 


1Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: February 11, 2022

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical